Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non-Current Assets (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Other Non-Current Assets for 16 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 54.23% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Dec 2025, down 54.23%, and an annual FY2025 reading of $1.4 million, down 69.01% over the prior year.
  • Other Non-Current Assets was $1.4 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $4.5 million in Q3 2024 and bottomed at $210000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $1.2 million, with a median of $274000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Assets surged 2023.81% in 2024, then crashed 69.66% in 2025.
  • Year by year, Other Non-Current Assets stood at $273000.0 in 2021, then fell by 23.08% to $210000.0 in 2022, then rose by 10.48% to $232000.0 in 2023, then surged by 1228.88% to $3.1 million in 2024, then crashed by 54.23% to $1.4 million in 2025.
  • Business Quant data shows Other Non-Current Assets for ARWR at $1.4 million in Q4 2025, $1.4 million in Q3 2025, and $1.4 million in Q2 2025.